论文部分内容阅读
目的探讨维吾尔族心力衰竭患者ACEI和β受体阻滞剂应用情况。方法 2004～2008年就诊于我院的维吾尔族心力衰竭患者308例,其中245例完成了随访,患者入选后均给予ACEI(卡托普利片)、β受体阻滞剂(卡维地洛片)、氢氯噻嗪片/呋塞米片、螺内酯片、地高辛片等药物常规治疗。随访患者出院后医生记录6个月、1年、2年ACEI、β受体阻滞剂应用情况及应用剂量,同时记录6min步行试验结果。记录随访患者心脏B超中左室舒末、左心室射血分数(EF%),并记录患者2年内再入院情况(入院次数)。按ACEI、β受体阻滞剂应用情况进行分为两组:组1为ACEI或β受体阻滞剂达到应用靶剂量、或两者均达到靶剂量;组2为ACEI、β受体阻滞剂均未达到应用靶剂量。结果对入选患者进行2年随访后,ACEI、β受体阻滞剂剂量、较出院时有所上升、左室舒末较出院时有所下降,6min步行试验结果较前有所上升。在随访的245例心力衰竭患者中,ACEI、β受体阻滞剂剂量达标率分别为31.72%、35.86%;ACEI、β受体阻滞剂剂量均达标率为15.86%。分组后,组2随访2年后左室舒末明显大于组1。组1患者较组2左室射血分数较高、6min步行试验结果较长,2年内再入院次数较少。结论加强心力衰竭患者随访的依从性,才能最大限度的达到ACEI、β受体阻滞剂应用的靶剂量,提高治疗效果。
Objective To investigate the application of ACE inhibitors and β-blockers in patients with heart failure in Uighur. Methods A total of 308 Uygur heart failure patients were treated in our hospital from 2004 to 2008. Among them 245 cases were followed up. All patients were given ACEI (captopril tablets) and β blockers (carvedilol Tablets), hydrochlorothiazide tablets / furosemide tablets, spironolactone tablets, digoxin tablets and other drugs conventional treatment. Follow-up of patients discharged after the doctor recorded 6 months, 1 year, 2 years of application of ACEI, β-blockers and application dose, while recording 6min walk test results. The follow-up of patients with heart B ultrasound in the left ventricular end-diastolic, left ventricular ejection fraction (EF%), and record the patient within 2 years of rehospitalization (admission). According to the application of ACEI and β-blocker, the patients were divided into two groups: group 1 was ACEI or β-blocker to reach target dose, or both of them reached target dose; group 2 was ACEI and β-receptor blocker Lag agent did not reach the target dose. Results After 2-year follow-up of selected patients, the dose of ACEI and β-blockers increased compared with that at discharge. The end-diastolic pressure of left ventricular end-diastolic was lower than that at discharge. The result of 6-minute walk test increased compared with that before discharge. Among 245 patients with heart failure, the compliance rates of ACEI and β-blockers were 31.72% and 35.86%, respectively. The compliance rate of ACEI and β-blockers was 15.86%. After grouping, left ventricular end-diastolic dimension was significantly greater in group 2 than in group 2 after 2 years of follow-up. Patients in group 1 had a higher left ventricular ejection fraction than patients in group 2, longer walk tests in 6 minutes, and fewer re-admission in 2 years. Conclusion To improve follow-up compliance of patients with heart failure, the target dose of ACEI and β-blockers can be maximally achieved and the therapeutic effect can be improved.